ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NTLA vs NEOG // FORWARD P/E MULTIPLE

Intellia Therapeutics Inc. (NASDAQ) VS. Neogen Corporation (NASDAQ) • 15-METRIC TALLY: NTLA 2 — NEOG 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NTLA VS. NEOG) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NTLA NEOG SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 46.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -0.60% -34.40 NEOG /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -21.35% 3.11% -24.46 NEOG /fcf-yield <GO>
Operating Margin -60.00% -2.50% -57.50 NEOG /operating-margins <GO>
Net Profit Margin -60.00% -0.90% -59.10 NEOG /net-margins <GO>
Revenue Growth (YoY) 16.90% -2.70% +19.60 NTLA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.17 1.45 -0.28 NEOG /balance-sheet <GO>
Piotroski F-Score Quality 4/9 7/9 -3.00 NEOG /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.4 45.3 +8.19 NTLA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.85B $2.68B -$822.6M NEOG /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NTLA REV NEOG REV NTLA GROSS % NEOG GROSS % NTLA FCF NEOG FCF
FY 2025 $67.7M $870.4M — 46.9% -$395.9M $83.2M
FY 2024 $57.9M $894.7M — 47.1% -$354.7M $58.2M
FY 2023 $36.3M $924.2M — — -$394.1M $35.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NTLA // BETA —
NEOG // BETA —